Breast Cancer Research and Treatment

, Volume 26, Issue 1, pp 55–65 | Cite as

Relationship between immunological parameters and survival of patients with liver metastases from breast cancer given immuno-chemotherapy

  • Seiji Yamasaki
  • Norimichi Kan
  • Takehisa Harada
  • You Ichinose
  • Yoshio Moriguchi
  • Li Li
  • Tomoharu Sugie
  • Hiroshi Kodama
  • Kohei Satoh
  • Kazuhisa Ohgaki
Report

Summary

We treated 33 patients with liver metastases from breast cancer by immuno-chemotherapy including adoptive cell transfer between 1987 and 1992. In this study, we examined the change of immunological parameters in the peripheral blood lymphocytes and interleukin-2 (IL-2)-cultured lymphocytes, in primary vs. metastatic breast cancer patients and before vs. after treatment. Moreover, we examined their correlation with therapeutic response and survival after treatment. The immunological parameters used werein vitro natural killer cell activity (% lysis of K562),in vitro autologous tumor-killing activity (% lysis against autologous freshly isolated tumor cells), and proliferation of lymphocytes stimulated with IL-2 and autologous sonicated tumor extract antigen in mixed culture (IL-2-enhanced MLTR). When compared with primary breast cancer patients, patients with liver metastases showed a significant decrease in % lysis of K562 and autologous tumor cells. After treatment, the stimulation index in IL-2-enhanced MLTR increased significantly from the pretreatment level and correlated with survival after treatment. Moreover, non-specific immunological parameters (performance status, lymphocyte count, and transferred cell count and proliferation rate of cultured lymphocytes) were significantly associated with response and prognosis.

Key words

autologous tumor killing activity breast cancer immuno-chemotherapy interleukin-2 mixed lymphocyte tumor reaction natural killer cell activity 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Clark GM, Sledge GW, Osborne CK, McGuire WL: Survival from first recurrence: Relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 5: 55–61, 1987Google Scholar
  2. 2.
    Okino T, Kan N, Nakanishi M, Satoh K, Mise K, Teramura Y, Yamasaki S, Hori T, Kodama H, Ohgaki K, Tobe T: The therapeutic effect of OK-432-combined adoptive immunotherapy against liver metastases from breast cancer. J Cancer Res Clin Oncol 116: 197–202, 1990Google Scholar
  3. 3.
    Yamasaki S, Okino T, Kan N, Satoh K, Mise K, Teramura Y, Harada T, Kodama H, Hori T, Ohgaki K, Tobe T: Factors influencing the response and survival of patients with liver metastases from breast cancer receiving OK-432-combined adoptive immunotherapy. J Cancer Res Clin Oncol 118: 157–162, 1992Google Scholar
  4. 4.
    Okamoto H, Minami M, Shoin S, Koshimura S, Shimizu R: Experimental anticancer studies, part XXXI. On the streptococcal preparation having potent anticancer activity. Jpn J Exp Med 36: 175–186, 1966Google Scholar
  5. 5.
    Talmadge JE, Herberman RB: The preclinical screening laboratory: Evaluation of immunomodulatory and therapeutic properties of biological response modifiers. Cancer Treat Rep 70: 171–182, 1986Google Scholar
  6. 6.
    Hoshino T, Iho S, Kura F, Uchida A:In vivo andin vitro biological effects of OK-432, a streptococcal preparation, on the augmentation of autologous tumor cell killing activity and cytokine production of lymphocytes and monocytes in malignant diseases. In: Micksche M, Klein E (eds) OK-432: A biological response modifier. Professional Postgraduate Services, Tokyo, 1986, pp 61–68Google Scholar
  7. 7.
    Kan N, Hori T, Okino T, Imai S, Ohgaki K, Tobe T: Synergistic anti-tumor effect of host's lymphocytes and lymphocytes cultured with IL-2 and OK-432-combined adoptive immunotherapy. In: Latis K (ed) The 14th International Cancer Congress. Karger, Basel, 1986, p 144Google Scholar
  8. 8.
    Hori T, Mise K, Kan N, Okino T, Satoh K, Yamasaki S, Teramura Y, Harada T, Ohgaki K, Kodama H, Tobe T: Therapeutic and life-prolonging effect of intrapleural injection with a streptococcal preparation, OK-432, and IL2-cultured effusion lymphocytes to breast cancer patients with malignant pleural effusion. Biotherapy 5: 21–29, 1992Google Scholar
  9. 9.
    Kan N, Okino T, Nakanishi M, Sato K, Mise K, Yamasaki S, Teramura Y, Ohgaki K, Tobe T: Therapeutic efficacy of sequential therapy with OK-432, cyclophosphamide, IL2-cultured lymphocytes andin vivo IL2 against advanced murine plasmacytoma. Biotherapy 1: 197–206, 1989Google Scholar
  10. 10.
    Ortaldo JR, Wintrout RH: Implications of potential positive correlation between autologous tumor-cell-killing activity and prognosis in lung cancer. J Natl Cancer Inst 82: 1663–1665, 1990Google Scholar
  11. 11.
    Uchida A, Kariya Y, Okamoto N, Sugie K, Fujimoto T, Yagita M: Prediction of postoperative clinical course by autologous tumor-killing activity in lung cancer patients. J Natl Cancer Inst 82: 1697–1701, 1990Google Scholar
  12. 12.
    Talmadge JE: Development of immunotherapeutic strategies for the treatment of malignant neoplasms. Biotherapy 4: 215–236, 1992Google Scholar
  13. 13.
    Nakanishi M, Kan N, Okino T, Satoh K, Mise K, Teramura Y, Yamasaki S, Ohgaki K, Tobe T: Comparison between crude interleukin-2 and recombinant interleukin-2 in maintaining killing activity of cultured lymphocytes. Biotherapy 2: 21–32, 1990Google Scholar
  14. 14.
    Morgan DA, Ruscetti FW, Gallo RC: Selectivein vitro growth of T lymphocytes from normal human bone marrows. Science 193: 1007–1008, 1976Google Scholar
  15. 15.
    Gillis S, Smith KA: Long term culture of tumour-specific cytotoxic T cells. Nature 268: 154–156, 1977Google Scholar
  16. 16.
    Kan N, Ohgaki K, Inamoto T, Kodama H: Anti-tumor and therapeutic effects of spleen cells from tumor-bearing mice cultured with T cell growth factor and soluble tumor extract. Cancer Immunol Immunother 18: 215–222, 1984Google Scholar
  17. 17.
    Inamoto T, Ohgaki K, Hikasa Y, Kodama H: Specific antitumor immunity in pre- and postoperative state and five year survival of breast cancer patients. Arch Jpn Chir 53: 345–352, 1984Google Scholar
  18. 18.
    Kan N, Okino T, Kodama H, Ohgaki K, Tobe T, Inamoto T: Breast cancer-specific immunity evaluated by a newin vitro method, IL-2 enhanced MLTR. J Jpn Surg Soc 88: 1624–1631, 1987Google Scholar
  19. 19.
    Peetz M, Swanson J, Moseley HS, Fletcher WS: Endocrine ablation and hepatic artery infusion in the treatment of metastases to the liver from carcinoma of the breast. Surg Gynecol Obstet 155: 395–400, 1982Google Scholar
  20. 20.
    Zinser JW, Hortobagyi GN, Buzdar AU, Smith TL, Fraschini G: Clinical course of breast cancer patients with liver metastases. J Clin Oncol 5: 773–782, 1987Google Scholar
  21. 21.
    Stehlin JS, Ipolyi PD, Greeff P, McGaff CJ, Davis BR, McNary L: Treatment of cancer of the liver: twenty years' experience with infusion and resection in 414 patients. Ann Surg 208: 23–35, 1988Google Scholar
  22. 22.
    Rosenberg SA: Immunotherapy and gene therapy of cancer. Cancer Res (suppl) 51: 5074s-5079s, 1991Google Scholar
  23. 23.
    North RJ: Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T-cells. J Exp Med 155: 1063–1074, 1982Google Scholar
  24. 24.
    Livingston PO, Cunningham-Rundles S, Marfleet G, Gnecco C, Wong GY, Schiffman G, Enker WE, Hoffman MK: Inhibition of suppressor-cell activity by cyclophosphamide in patients with malignant melanoma. J Biol Response Mod 6: 392–403, 1987Google Scholar
  25. 25.
    Formelli F, Rossi C, Sensi ML, Parmiani G: Potentiation of adoptive immunotherapy by cis-diamminedichloroplatinum(II), but not by doxorubicin, on a disseminated mouse lymphoma and its association with reduction of tumor burden. Int J Cancer 42: 952–957, 1988Google Scholar
  26. 26.
    Kan N, Okino T, Kodama H, Satoh K, Mise K, Yamasaki S, Teramura Y, Harada T, Ohgaki K, Tobe T: Long-term survival of patients with advanced breast cancer in relation to IL-2-added MLTR. Biotherapy 6: 672–674, 1992Google Scholar

Copyright information

© Kluwer Academic Publishers 1993

Authors and Affiliations

  • Seiji Yamasaki
    • 1
  • Norimichi Kan
    • 1
  • Takehisa Harada
    • 1
  • You Ichinose
    • 1
  • Yoshio Moriguchi
    • 1
  • Li Li
    • 1
  • Tomoharu Sugie
    • 1
  • Hiroshi Kodama
    • 1
  • Kohei Satoh
    • 1
  • Kazuhisa Ohgaki
    • 1
  1. 1.Laboratory of Oncologic Surgery, First Department of Surgery, Faculty of MedicineKyoto UniversityKyotoJapan

Personalised recommendations